ACE Technology Guidances

ACE Technology Guidances communicate recommendations from the MOH Drug Advisory Committee or the MOH Medical Technology Advisory Committee on the funding status and appropriate use of drugs, vaccines or medical technologies that have been evaluated by ACE. The guidances also include the Committee’s rationale for the funding recommendations, and key clinical and economic evidence which informed their deliberations. Plain English Summaries (PES) to explain ACE Technology Guidances are available for patients and the public.

Published on 04 Jan 2022
Last Updated on 04 Jan 2022
A- A+
Guidance Recommendations
The Ministry of Health's Drug Advisory Committee has recommended:
  • Carfilzomib 30 mg powder for solution for infusion;
  • Ixazomib 3 mg and 4 mg capsules; and
  • Pomalidomide 1 mg, 2 mg, 3 mg and 4 mg capsules
for previously treated multiple myeloma in line with specific clinical criteria.

Carfilzomib, ixazomib and pomalidomide should be used in line with the recommended treatment regimens listed in the Annex.

Subsidy status

Carfilzomib 30 mg powder for solution for infusion, ixazomib 3 mg and 4 mg capsules and pomalidomide 1 mg, 2 mg, 3 mg and 4 mg capsules are recommended for inclusion on the Medication Assistance Fund (MAF) in line with the abovementioned indication.

MAF assistance for carfilzomib will be implemented from 4 January 2022. MAF assistance for ixazomib and pomalidomide will be implemented from 1 September 2022.

MAF assistance does not apply to daratumumab 100 mg/5 ml and 400 mg/20 ml concentrate for solution for infusion and 1800 mg/15 ml solution for subcutaneous injection when used for previously treated multiple myeloma.

Clinical indications, subsidy class and MediShield Life claim limits for all drugs included in the evaluation are provided in the Annex.


PES Cancer drugs for previously treated multiple myeloma (Published 4 Jan 2022) Review of cancer drugs for previously treated multiple myeloma (4 Jan 2022)